Recently, Asymmetrex LLC joined forces with a new public-private Manufacturing USA Initiative, the Advanced Regenerative Manufacturing Institute (ARMI). ARMI highlighted Asymmetrex in its New Member Spotlight.
This member spotlight goes into detail about the crucial hurdle regenerative medicine is currently facing — a quantitative discipline for tissue stem cells. Dr. James Sherley speaks to ARMI about just this and how Asymmetrex’s technology will put an end to this:
“Achieving this shift in technical practice and conceptual perspective would immediately address several other hurdles that are more widely acknowledged. Examples include evaluating the efficacy of stem cell clinical trials with small sample size; developing industry standards for certifying the stability of transported stem cell therapies; defining the potency of stem cell treatments. The currently limited FDA guidance for human cell, tissue, and cellular and tissue-based products (HCT/P) might also be improved by incorporating a stem cell-specific dose basis,” Sherley explained.
Read the full Member Spotlight here!
Leave a Reply